Stent reconstruction in intracranial atherosclerotic disease related acute ischemic stroke results in high revascularization rates.


Journal

Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association
ISSN: 1532-8511
Titre abrégé: J Stroke Cerebrovasc Dis
Pays: United States
ID NLM: 9111633

Informations de publication

Date de publication:
Sep 2023
Historique:
received: 02 02 2023
revised: 16 06 2023
accepted: 20 06 2023
medline: 4 9 2023
pubmed: 16 7 2023
entrez: 15 7 2023
Statut: ppublish

Résumé

Intracranial atherosclerotic disease (ICAD) is a major cause of large vessel occlusion (LVO) in acute ischemic stroke (AIS). Our study aimed to analyze the effect of percutaneous transluminal angioplasty and stenting (PTAS) in patients with ICAD undergoing rescue treatment in terms of functional outcome and mortality rate at 90 days and compare the results to LVO with thromboembolic origins. A retrospective review of a mechanical thrombectomy (MT) single center database from 01/2019 to 09/2021 was carried out using chart review and angiogram analysis. From 469 acute stroke patients, 361 patients were enroled in the study, of whom twenty-four (6.6%) were diagnosed with underlying ICAD and treated with angioplasty and stent reconstruction (PTAS) with a standardized medication protocol. Successful reperfusion, peri-procedural complications, and functional independence at 90 days were collected as outcomes. There was no difference in age or admission National Institutes of Health Stroke Scale (NIHSS). Onset to groin puncture (median 460 vs 277 min, P = 0.019) was significantly longer in the ICAD group. The procedure time (median 73 vs 60 min, P = 0.137) did not differ. Successful reperfusion was achieved in 95.8% of ICAD and 91.1% of the remaining patients (P = 0.445). Functional independence (mRS ≤ 2) at 90 days was achieved in 45.8% (11/24) and 42.7% (144/337, (P = 0.767)). The mortality rates (mRS 6) at 90 days were similar (29.2% vs 29.4% (P = 0.983)). Despite significantly longer treatment delays, the outcome and revascularization rates of ICAD patients were similar to the thromboembolic cohort. Our proposed protocol of PTAS and medication protocol in ICAD was effective with a similar safety profile as MT in general.

Identifiants

pubmed: 37453214
pii: S1052-3057(23)00255-0
doi: 10.1016/j.jstrokecerebrovasdis.2023.107232
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

107232

Informations de copyright

Copyright © 2023 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Mara Z Thut (MZ)

Faculty of Medicine, University of Zurich, Zurich, Switzerland.

Nadine Rhiner (N)

Faculty of Medicine, University of Zurich, Zurich, Switzerland.

Patrick Thurner (P)

Department of Neuroradiology, Clinical Neurocenter, University Hospital Zurich, Frauenklinikstrasse 10, Zurich 8091, Switzerland.

Jawid Madjidyar (J)

Department of Neuroradiology, Clinical Neurocenter, University Hospital Zurich, Frauenklinikstrasse 10, Zurich 8091, Switzerland.

Tilman Schubert (T)

Department of Neuroradiology, Clinical Neurocenter, University Hospital Zurich, Frauenklinikstrasse 10, Zurich 8091, Switzerland.

Susanne Wegener (S)

Department of Neurology, Clinical Neurocenter, University Hospital Zurich, Frauenklinikstrasse 26, Zurich 8091, Switzerland.

Christoph Globas (C)

Department of Neurology, Clinical Neurocenter, University Hospital Zurich, Frauenklinikstrasse 26, Zurich 8091, Switzerland.

Andreas R Luft (AR)

Department of Neurology, Clinical Neurocenter, University Hospital Zurich, Frauenklinikstrasse 26, Zurich 8091, Switzerland; Cerneo Center for Neurology and Rehabilitation, Seestrasse 18, Vitznau 6354, Switzerland.

Zsolt Kulcsar (Z)

Department of Neuroradiology, Clinical Neurocenter, University Hospital Zurich, Frauenklinikstrasse 10, Zurich 8091, Switzerland. Electronic address: Zsolt.Kulcsar@usz.ch.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH